Moreover, low Pds5B expression levels predict better survival in patients with breast and ovarian cancer, as the loss of Pds5B sensitizes breast cancer cells to DNA-damaging chemotherapy (Brough et al., 2012). This evidence concerns the gene PDS5B and ovarian cancer.